Ironwood Pharmaceuticals
Company: Ironwood Pharmaceuticals, Inc.
Headquarters: Boston, Massachusetts, USA
Founded: 1998 (as Microbia, renamed 2008)
Ticker: IRWD (NASDAQ)
Employees: ~350
Market Cap: ~$1.5B (2024)
Overview
Mermaid diagram (expand to render)
Ironwood Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal (GI) disorders. The company is best known for [Linzess (linaclotide) for irritable bowel syndrome with constipation and chronic idiopathic constipation](/therapeutics/linaclotide), a guanylate cyclase-C (GC-C) agonist that has become a leading prescription therapy["@ironwood-corp"].
Ironwood's GI focus has significant relevance for [Parkinson's disease](/diseases/parkinsons-disease) patients, who experience among the highest rates of constipation of any patient population. The company's research into GC-C biology and GI motility mechanisms positions it to address autonomic-related GI dysfunction that affects 60-80% of PD patients["@pd-gi-review"].
Guanylate Cyclase-C (GC-C) Agonist Mechanism
Ironwood's core technology revolves around GC-C receptor agonism:
Mechanism of Action:
- Linaclotide binds to the GC-C receptor on the luminal surface of intestinal epithelial cells
- Activation increases intracellular cyclic GMP (cGMP) levels
- cGMP leads to: (1) accelerated GI transit, (2) increased intestinal fluid secretion, (3) reduced visceral sensitivity
- Minimal systemic absorption (acts locally in the GI tract)
Pharmacological Benefits:
- Restores natural bowel motility without colonic irritation
- Reduces abdominal pain through visceral analgesic effects
- Non-addictive, non-osmotic mechanism (unlike stimulant laxatives)
Relevance to Parkinson's Disease
Patients with [Parkinson's disease](/diseases/parkinsons-disease) suffer from constipation through multiple mechanisms:
Enteric nervous system involvement: Lewy bodies in myenteric and submucosal plexuses
Colonic transit delay: Reduced peristaltic contractions
Pelvic floor dysfunction: Dyssynergic defecation
Medication effects: Anticholinergics, dopaminergic agents[@linaclotide-gi]Linaclotide addresses the transit and secretion components, making it a targeted therapy for PD-associated slow-transit constipation. Unlike stimulant laxatives, linaclotide does not cause colonic inflammation and can be used chronically without the risk of laxative-induced colonic damage.
Product Portfolio
Linzess (Linaclotide)
| Attribute | Details |
|-----------|---------|
| Brand Name | Linzess |
| Generic Name | Linaclotide |
| Formulation | Oral capsules (72 mcg, 145 mcg) |
| Indication | IBS-C, Chronic Idiopathic Constipation |
| Dosing | Once daily on empty stomach, 30 min before first meal |
| FDA Approval | August 2012 (IBS-C), September 2012 (CIC) |
| Partner | AbbVie (formerly Forest Laboratories) for US commercialization |
| Revenue | >$1B annually (combined with Constella outside US) |
Efficacy:
- 12-18% improvement in spontaneous bowel movement (SBM) frequency vs. placebo
- Significant reduction in abdominal pain scores
- Onset of action within 1-2 weeks of consistent dosing
Safety Profile:
- Diarrhea (most common, ~20%)
- Abdominal pain
- Flatulence
- Minimal systemic absorption limits systemic side effects
Constella (Linaclotide, ex-US)
marketed as Constella outside the United States through AbbVie/partners, covering EU, Canada, and other markets.
Clinical Development
PD-Specific Research and Observations
While not specifically developed for PD, linaclotide has been evaluated in context of PD-associated constipation:
- Observational studies: PD patients with constipation treated with linaclotide showed improved bowel frequency and reduced constipation severity
- Mechanism fit: Addresses slow-transit component of PD constipation
- Levodopa absorption consideration: By improving GI transit, linaclotide may stabilize levodopa absorption and reduce motor fluctuation variability associated with constipation
Other Pipeline Programs
| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| IW-3300 | Functional GI disorders | GC-C agonist (novel formulation) | Preclinical |
| CNP analogs | Various GI targets | Guanylate cyclase modulation | Discovery |
Strategic Partnerships
AbbVie Collaboration
Ironwood partnered with AbbVie (formerly Forest Laboratories) for US commercialization of linaclotide:
- AbbVie handles sales, marketing, and distribution
- Ironwood retains manufacturing and receives royalties
- Collaboration extended through 2030+
Global Expansion
- EU/Canada: Constella marketed by multiple partners
- Japan: Partnered with Astellas for development and commercialization
- Other markets: Various regional partnerships
Related Pages
Disease and Mechanism Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Autonomic Dysfunction in Parkinson's Disease](/mechanisms/parkinsons-autonomic-dysfunction)
- [Gut-Brain Axis in Alpha-Synuclein Propagation](/mechanisms/gut-first-brain-first-alpha-synuclein-propagation)
- [Enteric Nervous System](/entities/enteric-nervous-system)
Treatment Pages
- [Linaclotide (Linzess) Therapeutic Profile](/therapeutics/linaclotide)
- [PD Gastrointestinal Dysfunction Treatments](/therapeutics/pd-gastrointestinal-dysfunction)
- [Parkinson's Non-Motor Symptom Treatments](/therapeutics/parkinsons-non-motor-symptoms)
Company Pages
- [Astellas Pharma](/companies/astellas-pharma) (linaclotide Japan partner)
- [PD Autonomic Dysfunction Treatment Companies](/companies/pd-autonomic-dysfunction-treatments)
References
[Ironwood Pharmaceuticals Corporate Overview (2024)](https://ir.ironwoodpharma.com)
[Fasano A, et al., Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/25998083/)
[Linzess (linaclotide) FDA Approval Label (2012)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202811lbl.pdf)
[Pfeiffer RF, Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)